BioCentury
ARTICLE | Clinical News

Opicinumab: Phase II data

June 13, 2016 7:00 AM UTC

Top-line data from the double-blind, international Phase II SYNERGY trial in 418 patients with relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS, showed that ...